Final Rpot

8/13/2019 Final Rpot

1/35

GLOBAL BUISINESS SCHOOL, HUBLI-580025

A Project Report On

Ratio Analysis

Lupin Limited

Report submitted to

prof Mahesh Bendigeri

GENS

GLOBAL BUSINESS SCHOOL, HUBLI

By

Monica Thakur

MBA13007049

Dec -2013

https://www.google.co.in/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&sqi=2&ved=0CCoQFjAA&url=http%3A%2F%2Fwww.lupinworld.com%2Fannual-report.htm&ei=oVrAUrL1DcS_rgejooGACQ&usg=AFQjCNGAACsVnaiA4GxB5yp28pBC30YdfQ&sig2=90qHMLrmgmADDLYfdQhTyw&bvm=bv.58187178,d.bmkhttps://www.google.co.in/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&cad=rja&sqi=2&ved=0CCoQFjAA&url=http%3A%2F%2Fwww.lupinworld.com%2Fannual-report.htm&ei=oVrAUrL1DcS_rgejooGACQ&usg=AFQjCNGAACsVnaiA4GxB5yp28pBC30YdfQ&sig2=90qHMLrmgmADDLYfdQhTyw&bvm=bv.58187178,d.bmk


2/35


EXECUTIVE SUMMARY

Financial ratio analysis as the name suggests, is the evaluation procedure of the performanceof the company. The evaluation is based on financial data and the data in the financial

statements is used for the financial performance analysis. Financial ratio analysis is the

process of evaluating the relationship between component parts of financial statement to

obtain a better understanding of the companys position and performance. The financial

statements extremely useful information to the extent the balance sheet mirrors the financial

position on a particular date in terms of the structure of assets, liabilities and owners equity,

etc and the profit and loss account shows the results of operations during a certain period oftime in terms of the revenues obtained and the costs incurred during the year.

The first task in the financial analysis is to select the information relevant to the decision

under consideration from the total information contained in the financial statements.

The second step involved in this is to arrange the information in a way to establish the

relationship

The final step is interpretation and drawing of inferences and conclusions. In short it is the process of selection, relation and evaluation.

Financial ratio analysis is an important tool. The other tools include the comparative analysis(i.e., inter- firm comparison). Time series analysis of ratios, common size statement analysis,indexed statement analysis, Du-point analysis.

Financial statements provide summarized view of the financial position and operation of the

company. Therefore, now a day it is necessary to all companies to know as well as to show

the financial soundness i.e. position and operation of company to their stakeholders. It is also

necessary to company to know their financial position and operation of the company.

In this report I made an effort to know the financial position of Indusind Bank, by using the

Annual Reports of the firm.

The Financial analysis of this report will show the Strength and weakness of the Indusind

Bank. Financial analysis will help the firm to take decision. Thus, we can say that, Financial


3/35


Analysis is a starting point for making plans before using any sophisticated forecasting and

planning.

TITLE OF THE PROJECT

A STUDY ON FINANCIAL RATIO ANALYSIS LUPIN LTD.

STATEMENT OF PROBLEMS

Management problem

As ratios provide a benchmark for companys against their own performance in industry. The

company wants to study the ratios and compare its performance of past with the present

performance with the help of ratio analysis, various items of financial statement that ensure

their existence as well as their future progress.

Research Problem:

To know the Financial Position of the company and its Liquidity Performance through

comparing three years financial performance by applying different financial Ratios

NEED FOR THE STUDY

The need for the study is to know the overall financial performance of the company

since 3 years.

The financial plan represents a blueprint of what the company proposes to do in thefuture.

The study reveals the use of various accounting ratios to explain the profitability

position.

OBJECTIVES OF STUDY

To know the LUPIN LTD financial performance based on ratios.

To find out the company efficiency based on past and present profitability ratios


4/35


LIMITATIONS OF THE STUDY:

The most important limitation of the study is that the study slowly depends on the

published data and documents such as balance sheet and income statement.

It was difficult to obtain confidential data from the concern department with a view point ofsecrecy that the company would like to observe.

METHODOLOGY:

The project information is collected from secondary data.

Secondary Data:

The various sources that were used for the collection of secondary data are

Various text books were used to understand the concepts of financial analysis.

Websites

To study the liquidity position of the bank To improve its future performance by analyzing its financial statement


5/35


INDUSTRY PROFILE

INTRODUCTION

Pharmaceuticals is a knowledge-based, technology-intensive industry that is uniquely placed

to develop and commercialise the outcomes of Australias long term investment in medical

research.

The Australian pharmaceuticals industry comprises bio-medical research, biotechnology

firms, originator and generic medicines companies and service related segments includingwholesaling and distribution. The industry employed over 40,000 people (one third inmanufacturing) in 2007-08 and turned over approximately $22 billion in 2009-10. It spent

$1.02 billion on research and development in 2008-09 and exported $4.12 billion in the 2009-10 financial year. There are over 150 separate firms listed as suppliers to the PharmaceuticalsBenefits Scheme (PBS).

The Australian market for pharmaceuticals is small in the context of global demand. Whilethe PBS allows for universal access to prescription products, the size of the population means

that sales are small.

Australia's population represents around 0.3 per cent of the world yet consumes around one per cent of total global pharmaceuticals sales. Thus in 2009 Australia was the 12th largest

pharmaceuticals market by sales, while being ranked 55th on population.

The expenditure on the PBS by Government has more than doubled over the last ten years,

from $3.2 billion in 1999-2000 to $8.3 billion (excluding patient contributions) in 2009-10.

In 2009-10, the largest firm by PBS sales was Pfizer. Its sales represent 14.4 per cent of thevalue of total sales made to the PBS. The top 10 suppliers by sales contributed more than 67

per cent of the value of total sales made to the PBS. Alphapharm is the largest firm by

number of prescriptions on the PBS (accounting for 14.3 per cent of all prescriptionsdispensed under the PBS). The top 10 firms by the number of prescriptions account for a total

of just over 70 per cent of total prescriptions written. These data suggest that the Australianmarket is serviced by a variety of suppliers which is consistent with the global industrystructure.
http://www.health.gov.au/internet/main/publishing.nsf/Content/Pharmaceutical+Benefits+Scheme+%28PBS%29-1http://www.health.gov.au/internet/main/publishing.nsf/Content/Pharmaceutical+Benefits+Scheme+%28PBS%29-1http://www.health.gov.au/internet/main/publishing.nsf/Content/Pharmaceutical+Benefits+Scheme+%28PBS%29-1http://www.health.gov.au/internet/main/publishing.nsf/Content/Pharmaceutical+Benefits+Scheme+%28PBS%29-1


6/35


Australian industry developments have gained worldwide recognition. They include:

CSL's development of a Swine Flu (N1H1) vaccine

Developments in discovering the Gardasil vaccine for Human Papilloma Virus through a partnership between Merck Sharp and Dohme and CSL

Australian biotechnology company Cytopia's $274 million deal with Novartis to develop

orally active, small molecule therapeutics targeting JAK3 kinase for the prevention oftransplant rejection and the treatment of multiple indications in autoimmune diseases suchas rheumatoid arthritis

The development by Biota Holdings of the flu drug Relenza.

Acrux's US$335 million deal (plus royalties) with Eli Lilly to market Acrux's US FDA

approved Axiron.

The Department encourages the development of an internationally competitive pharmaceuticals industry with policies which enhance the operating environment for the

industry by:

Providing policy advice to the Minister for Innovation, Industry, Science and Research(Innovation) on developments in the global pharmaceuticals industry and how they mightimpact on the Australian operating environment

Providing Secretariat support to the joint industry and Ministerial Pharmaceutical IndustryWorking Group

Assisting in implementing the recommendations of the Pharmaceuticals Industry Strategy

Group, in relation to increasing pharmaceuticals R&D, clinical trials and manufacturing inAustralia

Contributing to the Pharmaceutical Benefits Pricing Authoritys (PBPA) work on the pricing of pharmaceuticals for the PBS

Working with key industry stakeholders including the Pharmaceuticals Industry Council.

The pharmaceuticals industry spans a spectrum of activity from the technology intensive

R&D segment associated with innovative drugs through to the production of generic andover-the-counter medicines. The industry is dominated by horizontally and verticallyintegrated multinational entities and is more research intensive than most other industries.

Worldwide industry sales are projected to grow strongly at 7.5 per cent per annum over the

next five years. Espicom Business Intelligence estimate that the annual sales of
http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-pricing-pbparpt.htmhttp://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-pricing-pbparpt.htmhttp://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-pricing-pbparpt.htmhttp://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-pricing-pbparpt.htm


7/35


pharmaceuticals will reach US$852 billion in 2009 and project it will reach US$1,158.5 billion in 2014. The markets driving this change will be:

Central/Eastern Europe, with 9.7 per cent growth per annum

The Americas, with 7.3 per cent growth per annum

Middle East and Africa, with 8.6 per cent growth per annum

Asia/Pacific, with 4.9 per cent growth per annum

Western Europe, with 6.8 per cent growth per annum.

These data show that the global market for drugs is large and growing, that pharmaceuticals

industry sales are concentrated in developed countries, that half of all sales are made by thetop 10 global companies, but that there is still a reasonable degree of international

competition at an industry level.

Industry R&D activity

Developing a new drug is expensive. Current estimates of the full cost of bringing a newchemical or biological entity to market are around US$1.3 billion. Longer development and

approval times, larger and more complex clinical trials, increased expenditures on newtechnologies, and shifts in product portfolios towards riskier, more expensive therapeuticcategories have contributed to a real increase in the development costs.

Pharmaceuticals R&D expenditure is rising. Over the past two decades, the percentage ofsales allocated to R&D has increased from 11.9 per cent in 1980 to an estimated 18 per cent

in 2006 (for American owned firms). The number of products in development and thenumber of firms doing R&D are both rising; however R&D productivity continues to fall.

The industry spent $1.02 billion on R&D in Australia in 2008-2009. With 0.3 per cent of the

worlds population, Australia produces three per cent of global medical research and has a

proud history of seven Nobel laureates in medicine:

Howard Florey (1945: development of penicillin)

Frank Macfarlane Burnet (1960: research on organ transplantation)

John Eccles (1963: research on the transmission of nerve impulses)

Peter Doherty (1996: discoveries concerning the specificity of the cell mediated immunedefence)

Barry Marshall and J. Robin Warren (2005: discovery of the bacterium Helicobacter

pylori and its role in gastritis and peptic ulcer disease).


8/35


Elizabeth Blackburn (2009: research on telomeres, structures at the end of chromosomesthat protect the chromosome).

A feature of the Australian innovation system is the relatively high proportion of government

expenditure on R&D. In the health and medical area, this funding is allocated through avariety of R&D providers and there is considerable interaction between these entities. The

bulk of the funding is provided through:

The National Health and Medical Research Council (NHMRC)

Specialised research institutes, eg. Baker, Garvan, Queensland Institute of MedicalResearch

Universities

The Commonwealth Scientific and Industrial Research Organisation (CSIRO)

Hospitals

Cooperative Research Centres (CRCs).


9/35


Company Profile

Lupin Limited is an innovation led transnational pharmaceutical company producing

a wide range of quality, affordable generic and branded formulations and APIs for the

developed and developing markets of the world. The formation of Lupin in the year

1968 led to the vision and dream to fight life threatening infectious diseases and

manufacture drugs of highest national priority. Lupin is one of the fastest growing

Generic players globally. The company was named after the Lupin flower because of

the inherent qualities of the flower and what it personifies and stands for.

Lupin first gained recognition when it became one of the worlds largest manufacturers

of Tuberculosis drugs. Over the years, the Company has moved up the value chain

and has not only mastered the business of intermediates and APIs, but has also

leveraged its strengths to build a formidable formulations business globally.

Today, the Company has established global leadership position for its APIs and holds

a firm grip in the Cephalosporins, Cardiovascular and Anti-TB space.

Lupin first gained recognition when it became one of the worlds largest manufacturers

of Tuberculosis drugs. Over the years, the Company has moved up the value chain

and has not only mastered the business of intermediates and APIs, but has also

leveraged its strengths to build a formidable formulations business globally.


10/35


Today, the Company has established global leadership position for its APIs and holds

a firm grip in the Cephalosporins, Cardiovascular and Anti-TB space.

Lupin continues to enjoy global market leadership in Rifampicin, Pyrazinamide and

Ethambutol, as well as in Cephalosporins such as Cephalexin, Cefaclor and their

Intermediates. In FY 2010, the Company continued to record significant growth in the

7-ADCA and 7-ACCA family of products.

Lupin Ltd. is a key supplier of anti-TB formulations to the Global Drug Facility (GDF)

& maintained its premier position in the Anti-TB space during the current fiscal.

The Company has moved up the value chain since inception in terms of its products

and geographies. Currently, it commands a formulation business of over Rs 13,502

mn spread across the globe. Lupin has created a strong foothold in the Advanced

Markets of USA, Europe, Japan, Australia and Emerging markets of India and some

of the other Rest of World countries. It has onshore and offshore presence of its

products in 70 countries.

Today, Lupin is the 5th largest and fastest growing generics player in the US (by

prescriptions), the only Asian company to achieve that distinction. The company is

also the fastest growing top 10 pharmaceutical player in India, Japan & South Africa.

Its manufacturing units are located in Goa, Tarapur, Ankleshwar, Jammu,

Mandideep, Indore, Aurangabad and Kyowa in Japan. Benchmarked to International

standards, these facilities are approved by international regulatory agencies like US

FDA, UK MHRA, Japans MHLW, TGA Australia, WHO, and MCC South Africa

Business

In formulations it offers wide range of products for treatment of Cephalosporins, CVS,

CNS, Anti-Asthma, Anti-TB, Diabetology, Dermatology, GI, and many more. It

constitutes 84% of Lupins business. It has presence in USA, Europe, Japan,


11/35


Australia and emerging markets of India and some of the other rest of world

countries. Formulations make up 81% of our overall revenue composition.

In APIs segment it has a basket of product offerings for treatment of TB,

Cardiovasculars, Cephalosporins and many more.

FINANCIAL STATEMENT

A financial statement is a organized collection of data according to logical and

consistent accounting procedures. Its purpose is to convey understanding of some financial

aspects of business firm. It may show a position at a moment in time as in the case of b/s ormay reveal a series of activities over a given period of time as in case of income statement.

Financial statement are prepared for the management to deal with,

a. Status of investments.

b. Results achieved during a given period under review a financial statement generally

refers to the following;

1) Income Statement: The income statement also termed as (profit or loss account) is

generally considered to be the most useful of all financial statements. It explains what has

happened to a business as a result of operations between two balance sheet dates. It discloses

the revenue realized from the sale of goods and the costs incurred in the process of producing

the scheme. It tells the story of Progress or decline over given period and why and how an

indicated result was achieved.

2) Balance Sheet: it is statement of financial position of a business at particular momentof time and the claims of the owners and outside against those assets at that time.

3) Statement of Retained Earnings: the term retained earnings means the accumulated

excess of earnings over losses and dividends. The balance shown income statement is

transferred to the balance through this statement. After making necessary appropriations. It is

thus a connecting link between the B/s and income statement. This statement is also termed

as project and loss appropriation account in case of companies.


12/35


4) Statement of Changes in Financial Position: the balance sheet shows the financial

condition of the business at a particulars moment of time while the income statement

discloses the result of operations of business over a period of time. However for a better

understanding of the affairs of the business, it is essential to identify the movement ofworking capital or cash in and out of the business. This information is available in the

statement of changes in financial position of the business.

FINANCIAL RATIO ANALYSIS

Ratio analysis is a study of figures appearing in financial statements (Balance sheet and Profit

and Loss statement). Such figures have accounting significance and related to each other in a

manner that makes them mutually relevant. This aspect of the relativity is the central theme

of ratio analysis. This stems from the fact that absolute numbers do not mean much unless

compared one with another. The financial ratios therefore are used to express significant

relationship which exists between accounting numbers obtaining on a financial statement.

Ratios recognize the interrelationship which exists.

The study of financial ratios is an invaluable guide to the management in analyzing the

operations and the financial state of affairs of a business unit. Those who are concerned with

the performance of a unit are interested in being informed about its profitability, liquidity and

solvency. The ratio analysis is an attempt to obtain reliable indications in this respect. Thus

viewed the ratio analysis, as a tool of financial statement analysis, has to be purposive and

user oriented. Over the years the technique of ratio analysis has acquired more and more

usefulness and has found, accordingly, more and more users.

It is widely recognized that ratio analysis is an immensely valuable tool to highlight sensitivefinancial characteristics such as capital structure debt service, profitability, solvency, fund

and cash flows etc. The exercise of ratio analysis has other important uses in the areas of

audit, tax assessments, management control and budgeting and forecasting.

NEED FOR CAUTION IN INTERPRETATION OF RATIOS

Most of the ratios at best only give indications of a situation and as such they do not always

lead to precise evaluations. The analysis of ratios only acts as a pointer to a possible


13/35


disproportion. In order to avoid the possibilities of reaching unwarranted inferences it is

essential:

1. To select a proper ratio

2. Not to study a ratio in isolation i.e. indications from two or more ratios can be studied

in conjunction.

3. To subject the financial variables to further investigation where acute disproportion is

indicated by a ratio.

4. To call for further information relating to a financial data to verify its validity.

5. To be aware of the fact that it is not possible to state as to what constitutes, as ageneral rule, normal or ideal positions.

NEED FOR COMPARATIVE STUDY OF RATIOS

As in case of any financial number, ratio does not convey much meaning unless it iscompared with a similar ratio relating to a past period or to any other firm. Thus if a firm hadan operating profit ratio of 10% to its sales in 1999 this information by itself does not conveymuch.

But it would become more meaningful if it was compared with the similar ratio in the year1998 when it was 12% to its sales. One can then observe that the operating profit ratio has

dwindled in 1999 as compared to 1998. Therefore ratios relating to a firm can be studied in

comparison with similar ratios:

1) of the same firm relating to earlier periods

2) of another firm

3) representing industrial averages

4) projected in the budgets

5) set as targets


14/35


ADVANTAGES OF FINANCIAL RATIO ANALYSIS

i)The financial ratio analysis serves as an invaluable aid to the management in analyzing theoperations and state of affairs of a business enterprise,

ii)The financial ratio analysis being an important tool of financial statement analysis, various

groups of people interested in financial aspects an

iii)enterprise (such as investors, lenders, employees, government, stock exchange authorities

etc.,) use this with advantage for the purposes relevant to them,

iv)This technique of financial statement analysis can be used with good effect in preparing

budgets, forecasting and planning, projecting working capital requirements etc.,

v)It helps to analyze and reliably indicate financial health of a company by focusing on its

profitability, liquidity and solvency, debt-servicing, utilization of resources etc.,

vi)Proper evaluation of performance and position is possible by comparing financial ratios of

a firm with those of another firm or by comparing ratios of a firm for a period with those for

another period.

vii)It becomes easier to assign responsibilities to functional heads in a management team,

viii)It helps in presenting plethora of accounting data in a systematic and morecomprehensible manner.


15/35


16/35


AdvancesDeffered Credit 0 0 0 0 0 0 0 0 0Current Liabilities 14.01 147.09 233.48 273.72 296.21 333.06 880.29 1,193.81 1,332.67Provisions 5.87 18.55 11.85 57.57 69.25 39.98 199.36 237.84 311.06

Total CL & Provisions 19.88 165.64 245.33 331.29 365.46 373.04 1,079.65 1,431.65 1,643.73Net Current Assets 56.5 528.79 495.26 464.98 281.85 303.02 1,654.52 1,974.96 2,460.19Miscellaneous Expenses 1.31 0 0 0 0 0 0 0 0Total Assets 145.34 977.86 967.42 969.86 825.14 941.14 4,132.12 4,727.06 5,402.00Key Financial Ratios

Mar '00 Mar '01Mar

'02Mar

'03Mar

'04Mar

'05 Mar '11 Mar '12 Mar '13

Investment ValuationRatiosFace Value 10 10 10 10 10 10 2 2 2Dividend Per Share 1 3.5 5 5 6.5 6.5 3 3.2 4Operating Profit PerShare (Rs) 5.35 534.55 47.07 46.43 68.13 34.62 21.48 23.05 42.1Net Operating Profit PerShare (Rs) 17.34 2,958.56 222.86 256.56 293.25 289.5 100.74 120.56 159.15Free Reserves Per Share(Rs) 5.88 580 40.1 57.65 82.35 96.29 -- -- --Bonus in Equity Capital -- -- -- -- -- -- 44.99 44.94 44.85

Profitability RatiosOperating ProfitMargin(%) 30.84 18.06 21.12 18.09 23.23 11.95 21.32 19.11 26.45Profit Before InterestAnd Tax Margin(%) 23.42 15.81 18.49 15.63 20.67 9.01 18.93 16.65 24.26Gross Profit Margin(%) 15.38 11.14 14.31 12.29 19.2 10.44 19 16.66 24.34Cash Profit Margin(%) 9.83 9.35 10.63 9.5 14.8 10.02 20.25 14.91 19.73Adjusted CashMargin(%) 11.18 10.16 11.32 10.08 14.69 10.03 20.25 14.91 19.73Net Profit Margin(%) 3.46 7.15 8.05 7.08 12.34 7.19 17.95 14.92 17.63Adjusted Net ProfitMargin(%) 3.17 7.79 8.73 7.65 12.24 7.2 17.95 14.92 17.63Return On CapitalEmployed(%) 10.42 13.63 17.29 16.82 30.24 12.38 21.07 19.05 32.52Return On Net Worth(%) 3.15 16.64 21.26 19.11 32.58 16.86 25.69 21.53 26Adjusted Return on NetWorth(%) 2.94 20.6 23.21 20.52 32.3 16.87 25.67 17.99 26Return on AssetsExcluding Revaluations 19.34 1,100.70 82.82 95.26 111.61 124.69 70.66 83.61 108.3Return on AssetsIncluding Revaluations 19.34 1,100.70 82.82 95.26 111.61 124.69 70.66 83.61 108.3

Return on Long TermFunds(%) 11.62 17.55 21.3 20.64 39.22 17.48 25.8 23.28 36.03


17/35


Liquidity And SolvencyRatiosCurrent Ratio 1.53 1.32 1.24 1.15 0.87 0.73 1.1 1.19 1.59Quick Ratio 3.16 3.31 2.43 1.97 1.18 1.14 1.75 1.59 1.69Debt Equity Ratio 1.2 2.02 1.91 1.54 0.84 0.88 0.31 0.27 0.11Long Term Debt EquityRatio 0.97 1.44 1.36 1.07 0.42 0.33 0.07 0.04 0.01Debt Coverage RatiosInterest Cover 1.41 2.23 2.69 2.66 4.85 4.27 31.58 31.41 52.8Total Debt to OwnersFund 1.2 2.02 1.91 1.54 0.84 0.88 0.31 0.27 0.11Financial ChargesCoverage Ratio 1.71 2.44 2.94 2.95 5.08 4.8 35.37 36.01 57.31Financial ChargesCoverage Ratio Post Tax 1.59 2.27 2.47 2.54 4.19 4.77 34.16 33.65 43.38

Management EfficiencyRatiosInventory Turnover Ratio 4.48 5.73 6.25 7.27 5.49 4.73 5.34 4.79 5.35Debtors Turnover Ratio 1.18 4.99 2.86 3.1 4.24 5.15 4.18 3.95 4.23Investments TurnoverRatio 5.47 6.51 7.03 8.34 6.23 5.46 5.34 4.79 5.35Fixed Assets TurnoverRatio 0.66 3.2 1.99 2.15 2.28 2.01 2.42 2.32 2.59Total Assets TurnoverRatio 0.4 0.86 0.92 1.06 1.43 1.24 1.09 1.14 1.32Asset Turnover Ratio 0.38 1.49 0.92 1.06 1.31 1.32 1.19 1.22 1.41

Average Raw MaterialHolding 43.91 46.85 34.26 30.05 45.76 70.54 -- -- --Average Finished GoodsHeld 15.88 25.94 29.75 23.18 28.34 32.61 -- -- --Number of Days InWorking Capital 233.03 227.36 199.3 162.54 86.2 93.87 139.32 138.55 126.07Profit & Loss AccountRatiosMaterial Cost

Composition 46.44 51.33 48.55 53.07 50.37 51.76 42.74 44.15 41.05Imported Composition ofRaw MaterialsConsumed 22.23 41.29 41.83 42.71 57.76 52.9 42.58 38.86 38.35Selling Distribution CostComposition 0.99 10.23 10.74 7.63 9.39 9.26 -- -- --Expenses as Compositionof Total Sales 21.05 27.7 34.66 40.23 48.96 49 59.05 60.25 62.82Cash Flow IndicatorRatiosDividend Payout Ratio

Net Profit 196.42 26.81 29.85 31.2 20.16 35.34 19.21 20.65 16.61Dividend Payout Ratio 59.25 20.03 22.51 23.19 16.81 25.36 17.02 17.74 14.84


18/35


Cash ProfitEarning Retention Ratio -114.18 75.45 72.51 71.16 79.67 64.71 80.78 75.28 83.39Cash Earning RetentionRatio 39.23 81.26 78.86 78.14 83.07 74.67 82.98 79.34 85.16AdjustedCash FlowTimes 11.75 7.23 6.19 5.65 2.17 3.74 1.07 1.23 0.39

Earnings Per Share 0.62 207.71 17.71 18.08 36.37 21.02 18.15 18.01 28.16Book Value 19.73 1,100.70 82.82 95.26 111.61 124.69 70.66 83.61 108.3

FINANCIAL RATIOS OR TYPES OF FINANCIAL RATIOS


19/35


Financial ratios quantify many aspects of a business and are an integral part of

financial statements analysis. Financial ratios are categorized according to the financial

aspect of the business which the ratio measures, financial ratio can be divided for

convenience into following different basic categories.

1. Liquidity Ratios

2. Leverage Ratios

3. Activity Ratios

4. Profitability Ratios

5. Other Ratios

LIQUIDITY RATIOS

Liquidity Ratios refers to the firms ability to satisfy its short term obligations or current

liabilities as they become due, liability will be usually of one year. It reflects the financial

strength/solvency of a firm.

A firm should ensure that it does not suffer from lack of liquidity and also that it does nothave excess liquidity. A failure of company to meet its obligation due to lack of sufficient

liquidity, will result in poor credit worthiness. A very high degree of liquidity is also bad

because, idle asset earn nothing. The firm funds will be unnecessary tide up in current assets.

Therefore, it is in necessary to strike a proper balance between high liquidity and lack of

liquidity.The ratios which indicate the liquidity of a firm are i. Current Ratio, ii. Quick Ratio,

iii. Interval Ratio, iv Net Working Capital Ratio, v. Absolute Liquidity Ratio.

Current ratio :


20/35


Measures the ability of an entity to pay its near-term obligations usually as within one year.Though the ideal current ratio depends to some extent on the type of business, a general ruleof thumb is that it should be at least 2:1. A lower current ratio means that the company maynot be able to pay its bills on time, while a higher ratio means that the company has money in

cash or safe investments that could be put to better use in the business. The current ratio is theratio of the current assets and current liabilities. It is calculated by dividing current assets bycurrent liabilities.

Current Ratio= Current assetsCurrent liabilities

Year Current assets Current liabilty Total

2011 145.34 145.34 290.682012 977.86 977.86 1955.722013 967.42 967.42 1934.84

LEVERAGE OR CAPITAL STRUCTURE RATIOS:

Leverage ratios look at the extent that a company has depended upon borrowing to finance itsoperations. As a result, these ratios are reviewed closely by bankers and investors. Mostleverage ratios compare assets or net worth with liabilities. A high leverage ratio mayincrease a company's exposure to risk and business downturns, but along with this higher riskalso comes the potential for higher returns. Some of the major measurements of leverageinclude:

0

500

1000

1500

2000

2500

2011 2012 2013

Current ratio

290.68 1955.72 1934.84


21/35


22/35


Debt Ratio= Total DebtTotal Assets

Year Debt Ratio2011 1.2

2012 2.02

2013 1.91

Proprietary Ratio:

Proprietary Ratio= Proprietors Funds

Total Assets

Year Proprietary ratio Total

2011 866.06 18488.58

2012 1056.79 22028.6

2013 1349.21 24668.54

0

0.5

1

1.5

2

2.5

2011 2012 2013

Debt equity ratio

1.2 2.02 1.91


23/35


PROFITABILITY RATIOS

There are many measures of profitability. As group, these measures enable the analyst toevaluate the firms profits with respect to a given level of sales, a certain level of assets, orthe owners investment. Owners, creditors and management pay close attention to boosting

profits. The management of the firm is naturally eager to measures its operating efficiency.Similarly the owners invest their funds in the expectation of reasonable returns. Profitabilityratio measures the firms use of its assets and control of its expenses in order to generate anacceptable rate of return. Following are the ratio designed to provide answers to questionssuch as,

i. Is the profit earned by the firm adequate?

ii. What rate of return does it represents?

iii. What is the rate of profit for various divisions and segment of firm

iv. What is the amount paid in dividends?

v. What is the earning per share?

vi. What is the rate of return to equity shareholders and so on.

Profitability ratios can be determined on the basis of either sales or investment. The profitability ratios in relation to sales are

i. Gross Profit MarginGross profit is the difference between sales and the manufacturing cost of goods sold. The

gross profit margin reflects the efficiency with which management produces each unit of

0%

10%

20%

30%

40%

50%

60%

70%80%

90%

100%

2011 2012 2013

Proprietary ratio

866.06 1056.79 1349.21


24/35


product. This ratio indicates the average spread between the cost of goods sold and the sales

revenue. A high gross profit margin ratio is a sign of good management.

Sales Cost of Goods Sold

Gross Profit Margin = --------------------------------------Sales

Gross Profit = Sales Cost Of Goods Sold.

Year Gross profit2011 21.322012 19.112013 26.45

0

5

10

15

20

25

30

2011 2012 2013

Gross profit

Series1


25/35


ii. Operating Profit Margin

The operating profit margin measures the percentage of each sales rupee remaining after all

costs and expenses other than interest, taxes and preferred stock dividends are deducted. It

shows the pure profit earned on each sales rupee. A high operating profit margin is preferred.

Operating profitOperating Profit Margin = ----------------------------

Sales

Year Operating Profit Margin

2011

20122013

iii. Net Profit Margin

The net profit margin measures the percentage of each sales rupee remaining after all cost

and expenses, including taxes and preferred stock dividend, have been deducted, the higher

the firms net profit margin, the better.

Profit After Tax Net Profit Margin = -------------------------

Sales

year Net Profit Margin 2011 17.95

2012 14.922013 17.63


26/35


iv. Operating Expenses

Operating expenses ratio explains the changes in the profit margin (EBIT to sales) ratio.

A higher operating expenses ratio is unfavorable since it will leave a small amount of income

to meet interest, dividends, etc. the operating expenses ratio is a yardstick of operating

efficiency, but it should be used cautiously. It is affected by number of factors such as

external uncontrollable factor, internal factor, employee and managerial efficiency all of

which are difficult to analyze.

Operating ExpensesOperating Expenses Ratio = -------------------------------

Sales

Year Operating Expenses Ratio

2011 21.482012 23.052013 42.1

0

2

4

6

8

10

12

1416

18

20

2011 2012 2013

Net Profit Margin

Series1


27/35


Profitability in relation to investments is measured by following ratios.

v. Return on Investment / Return on Total Assets

The term investment may be refer to total assets or net assets, the funds employed in net

assets is known as capital employed which is equal to net worth + total debt.

ROI = ROTA (Rate on Total Assets) RONA (Rate on Net Assets)

EBITROI = ROTA = ----------------------------

Capital Employed

Year ROI

2011 70.66

2012 83.612013 108.3

0

5

10

15

20

25

30

35

40

45

2011 2012 2013

Operating Expenses Ratio

21.48 23.05 42.1


28/35


vi. ROE (Return on Equity)

The return on common equity measures the return earned on the common stockholdersinvestment in the firm. Generally, higher the return, the better.

PATROE = -----------------

Net WorthYear ROE 2011 21.07

2012 19.052013 32.52

0

20

40

60

80

100

120

2011 2012 2013

ROI

Series1

0

5

10

15

20

25

30

35

2011 2012 2013

ROE

ROE


29/35


Return on Total Assets:

This measures the profitability in terms of relationship between net profit and the total assets.

Return on Total Assets = Profit after Tax x 100Average Total Assets

Year Return on Total Assets

2011 70.662012 83.61

2013 108.3

Return on Equity :

In this ratio profitability is measures by dividing the net profit after taxes by the average

shareholders / equity. The average shareholders equity includes equity, reserves and surplus

excluding miscellaneous expenditure.

Return on Equity =Net Profit after Taxes x 100Average Net Worth

Year Return on Equity

2011 25.672012 17.992013 26

0

20

40

60

80

100

120

1 2 3

Return on Total Assets

Series1


30/35


DEBT TO TOTAL CAPITALIZATION RATIO :

This ratio determines the proportion of total capitalization, which is the firms

permanent financing, that long term represents. Generally, firms with lower debttotal

capitalization ratios are considered better credit risks because a larger equity cushion exists to

protect creditors.

Debt To Total Capitalization Ratio = Long Term DebtLong Term Debt+ Stockholders Equity

Year Debt To Total Capitalization Ratio 2011

20.252012

14.912013 19.73

INTERPRETATION

The graph indicates that there is no more fluctuation in ratio i.e 0.648, 0.649 and

0.648 and it is same for the year 2011 and2013

Dividend per Share:

This ratio shows how much dividend is paid per share to the ordinary shareholders.

Dividend per Share =Actual Dividend Paid To the Equity Shareholders Number of Ordinary Equity Shares

Year Dividend per Share

2011 32012 3.22013 4

This shows how much is retained in the business and how much is distributed amongst he

shareholder


31/35


32/35


Dividend Payout Ratios:

It measures the relationship between the earnings belonging to the ordinary shareholders andthe dividend paid to them. This is calculated by dividing the actual dividend paid by the net

profit available to them. Alternatively, it can be found out by dividing the dividend per share

by the earnings per share.

Dividend Payout Ratio = Actual Dividend Paid to the Equity Shareholders Net profit available to the equity shares holder

Year Dividend Payout Ratio

2011 19.21

2012 20.652013 16.61

Cost of deposits ratio

Cost of deposits ratio = Interest paid on depositsAverage deposits

Year Cost of deposits ratio

2011 42.582012 38.862013 38.35


33/35


Suggestion

Lupin ltd must thoroughly study the accounts of the company where there is a chanceof manipulation.

The current assets to total assets is increased which means the company is paying

more attention to its current assets. They should improve the utilization of current

assets as it will be required for day to day business.

Lupin ltd should have the schemes to entertain the demand for financial assistance

from the businesses which are in need of small amount of loan facilities.

Increase manpower (with credit and recovery skills) at the sector.

It must follow some rules to improve it financial strength

Accoriding return on total assets ratio the company is utilizing its total assets at

optimum level to get higher profitability so it is advised to carry in same level.


34/35


CONCLUSION

It has been an excellent opportunity for me to carry out the study on Ratio Analysis at

Lupin ltd . It has helped to a great extent to have an insight into the practical realities of the

subject. The project carried out Lupin ltd has provided me with an in depth knowledge

insight into it also provided me an opportunity to study and analyze the various ratios.

Though thisr has coin to coin competition t tis is providing a satisfied service to their

customers and with the latest technology as well as the new strategies, it is coming up with

new products keeping in mind about customers as a lay man and providing service to them , it

is growing rapidly

Findings and suggestions made in the report, if taken care of, will result in better performances of Lupin ltd .


35/35

BIBLIOGRAPHY

Annual report of the company

Financial Management M.Y Khan & P. K Jain

Financial Management Battacharaya

www.Google.com

www.lupin.com
http://www.google.com/http://www.google.com/http://www.lupin.com/http://www.lupin.com/http://www.lupin.com/http://www.google.com/

Final Rpot

Documents

Transcript of Final Rpot